"The Company is well advanced in its planning for the next trial of ATL1103 and expects to be in a position to commence the trial by or prior to mid 2012 with interim results potentially available in early to mid 2013."
Whilst i love all the speculation the fact is the paragraph above from the 9/2/2012 announcement.
With regards to funding speculation could go from CR to LajollaCove type funding , to pharma company partnership to closing up shop altogether.
Nooone knows so all this hype and speculation is pie in the sky.
What we do know is this:
Fact 1): ATL1103 expects to be in a position to commence the trial by or prior to mid 2012 with interim results potentially available in early to mid 2013.(And thats only phase2 trial.Phase 3 will proceed after Phase3.
Fact2) noone has any idea with funding and ANP are in need of capital to even get phase2 started.
IMO its either a CR plus consolidation of capital of a convertable note similar to other bios re LaJollaCove type situation.
Cheers
Rob
licensing due diligence, page-4
-
- There are more pages in this discussion • 9 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
